Where do we stand with IPF treatment?

Despite receiving ‘weak no’ recommendations in the updated guidelines on treating patients with Idiopathic Pulmonary Fibrosis (IPF), two key treatment options are pirfenidone and N-acetylcysteine (NAC), and both are used in clinical practice. The efficacy of pirfenidone is supported by a number of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Albera, C, Ferrero, C, Rindone, E, Zanotto, S, Rizza, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643087/
https://www.ncbi.nlm.nih.gov/pubmed/23734956
http://dx.doi.org/10.1186/1465-9921-14-S1-S7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643087/
https://www.ncbi.nlm.nih.gov/pubmed/23734956
http://dx.doi.org/10.1186/1465-9921-14-S1-S7

Ejemplares similares